Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Thrombocytopenia × oprelvekin × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Thrombocytopenia 1

Interventions

eltrombopag 5 romiplostim 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 oprelvekin 1 lusutrombopag 1 avatrombopag 1 Interleukin-11 1 Injections 1 Gemcitabine 1 Daunorubicin 1 Cytarabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01663441 2020-09-16

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Beijing Northland Biotech. Co., Ltd.

Phase 3 Completed

Classical hematology

Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡